/ mRNA
/ Market Analysis
Why Is Moderna (MRNA) Stock Down Premarket? FDA Rejects Flu Vaccine Filing
Moderna stock dropped over 9% in premarket trading after the FDA refused to review its mRNA-based flu vaccine, citing inadequate study design.
February 11, 2026
Why Is Moderna (MRNA) Stock Up Today: Merck Partnered Vaccine Cuts Recurrence Risk
Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by 49%.
January 21, 2026
Moderna Stock Drops as FDA Signals New Restrictions on Vaccine Approvals
Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays for new vaccines.
December 01, 2025
Why is Moderna’s Stock Gaining in Premarket Trading Today?
Moderna stock jumped in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine.
June 02, 2025
Trump Admin. Reconsiders $590M Funding for Moderna’s Bird Flu Vaccine
The Trump administration is reconsidering a $590 million contract with Moderna for bird flu vaccine development.
February 27, 2025More from The Tokenist / mRNA
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
September 12, 2024
Stocks to Watch Today: MRNA, META, and AMAT
August 01, 2024
Stocks to Watch Today: TSLA, RIVN, and Moderna
June 26, 2024
Back to 
